Allergy Therapeutics PLC Pledge of Shares (7037T)
27 March 2021 - 3:39AM
UK Regulatory
TIDMAGY
RNS Number : 7037T
Allergy Therapeutics PLC
26 March 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Pledge of Shares
Allergy Therapeutics (AIM:AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, announces
that today, it was notified that Manuel, Llobet, Chief Executive
Officer and PDMR, entered into a personal loan agreement whereby
security over 600,000 ordinary shares of 0.01 pence each in the
capital of the Company was granted in favour of Banco
Santander.
There is no change in Mr Llobet's beneficial shareholding in the
Company and he continues to have an interest and voting rights in
3,325,000 ordinary shares representing approximately 0.52% of the
issued share capital of the Company.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Manuel Llobet
--------------------- ----------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Manuel Llobet - Chief Executive Office and PDMR
--------------------- ----------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- ----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--------------------- ----------------------------------------------------
b) LEI LEIR97215202003301009534776
--------------------- ----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument,
type of instrument
--------------------- ----------------------------------------------------
b) Identification GB00B02LCQ05
code
--------------------- ----------------------------------------------------
c) Nature of the Mr Llobet entered into a personal loan agreement
transaction with Banco Santander whereby security over 600,000
ordinary shares in the Company. Mr Llobet remains
the beneficial owner of the shares subject to
the pledge and retains full voting rights.
--------------------- ----------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s) n/a 600,000
--------------------- ----------------------------------------------------
e) Aggregated
information n/a
--------------------- ----------------------------------------------------
f) Date of the 26 March 2021
transaction
--------------------- ----------------------------------------------------
g) Place of the Outside a trading venue
transaction
--------------------- ----------------------------------------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines, that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.600 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFZGZFVVNGMZM
(END) Dow Jones Newswires
March 26, 2021 12:39 ET (16:39 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024